Three phase 3 randomized clinical trials (RCTs)1,2,3 investigated adding PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors to platinum-based chemotherapy as first-line treatment in advanced urothelial carcinoma. The gene discussed is PDCD1; the disease is urothelial carcinoma.